279
Views
21
CrossRef citations to date
0
Altmetric
Drug Evaluation

Lacosamide for pain

, MD
Pages 1129-1134 | Published online: 05 Aug 2010

Bibliography

  • Bergouignan M, D'Aulnay N. Effect of diphenyl-hydantoinate salt on essential trigeminal neuralgia. Rev Otoneuroophthalmol 1951;23:1202-5
  • Murphy JP. Tegretol (carbamazepine): a new and effective medical treatment of trigeminal neuralgia, with a not concerning its use in the syndrome of thalamic hyperpathia. Med Ann Dist Columbia 1966;35:658-63
  • Lutz EG. Treatment of tic doloureaux with G-32883 (carbamazepine). Dis Nerv Syst 1966;27:600-3
  • Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1966;15:129-36
  • McQuay H, Tramer M, Nye BA, A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-27
  • Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73:157-69
  • Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther 2008;326:89-99
  • Errington AC, Coyne L, Stohr T, Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006;50:1016-29
  • Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in a rat model for peripheral diabetic neuropathy. Eur J Pharmacol 2006;539:64-70
  • Hao JX, Stohr T, Selve N, Lacosamide, a new anti-epileptic, alleviates neuropathic pain like behaviours in rat models of spinal cord or trigeminal nerve injury. Eur J Pharmacol 2006;553:135-40
  • Bee LA, Dickenson AH. Effects of lacosamide, a novel sodium channel modulator on dorsal horn neuronal responses in a rat model of neuropathic pain. Neuropharmacology 2009;57:472-9
  • Stohr T, Krause E, Selve N. Lacosamide displays a potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain 2006;10:241-9
  • Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain. Arthritis Res Ther 2007;9:R14
  • Beyreuther BK, Geis C, Stohr T, Sommer C. Antihyperalgesic efficacy of lacosamide in a rat model fro muscle pain induced by TNF. Neuropharmacology 2007;52:1312-17
  • Beyreuther BK, Callizot N, Brot MD, Antinociceptive efficacy of lacosamide in rat models for tumor and chemotherapy-induced cancer pain. Eur J Pharmacol 2007;565:98-104
  • McCleane G, Koch B, Rauschkolb C. Does SPM 927 have an analgesic effect in human neuropathic pain? Neurosci Lett 2003;352:117-20
  • Rauck RL, Shaibani A, Biton V, Lacosamide in painful diabetic peripheral neuropathy: a phase II double-blind placebo-controlled study. Clin J Pain 2007;23:150-8
  • Wymer JP, Simpson J, Sen D, Bongardt S; Lacosamide SP742 Study Group. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed dose regimens. Clin J Pain 2009;25:376-85
  • Shaibani A, Fares S, Selam JL, Lacosamide in painful diabetic neuropathy: an 18-week double blind placebo controlled trial. J Pain 2009;10:818-28
  • Ziegler D, Hidvegi T, Gurieva I, Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010;33:839-41
  • Shaibani A, Biton V, Rauck R, Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial. Eur J Pain 2009;13:458-63
  • Biton V. Lacosamide for the treatment of diabetic neuropathic pain. Expert Rev Neurother 2008;8:1649-60
  • European Medicines Agency. Questions and answers on the withdrawal of the marketing application for Lacosamide Pain UCB Pharma. London: Doc.Ref.EMEA/522632/2008
  • Wiffen PJ, Collins S, McQuay HJ, Cochrane Database Syst Rev 2010;1:CD001133
  • Moore RA, Straube S, Wiffen PJ, Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009;3:CD007076

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.